# A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

> **NCT04303741** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 46 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib
- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT04303741
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-25
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-08-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04303741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04303741, "A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04303741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*